March 25, 2024 Sequana Medical announces three month follow-up data from MOJAVE non-randomized cohort confirming dramatic improvement in diuretic response and virtual elimination of loop diuretics following DSR® therapy Non-regulated EN NL
February 28, 2024 Strong data from DSR® proof-of-concept studies in heart failure accepted for late-breaking presentation at THT 2024 Non-regulated EN NL
January 29, 2024 Sequana Medical announces FDA acceptance for substantive review of the Premarket Approval application for alfapump® in recurrent or refractory ascites due to liver cirrhosis Non-regulated EN NL
January 23, 2024 Sequana Medical announces DSMB approval to start randomized MOJAVE cohort – US Phase 1/2a study of DSR® 2.0 for treatment of heart failure Inside information, Regulated EN NL
January 3, 2024 Sequana Medical granted US CPT® III reimbursement codes for alfapump® system Non-regulated EN NL
December 28, 2023 Sequana Medical submits Premarket Approval application to US FDA for alfapump® in recurrent or refractory ascites due to liver cirrhosis Inside information, Regulated EN NL
November 29, 2023 Sequana Medical announces positive data from non-randomized cohort in US Phase 1/2a MOJAVE study of DSR® 2.0 for treatment of heart failure Inside information, Regulated EN NL
November 10, 2023 Sequana Medical announces results of Extraordinary General Meeting of Shareholders Regulated EN NL